- Fast Delivery
- 3rd Party Tested
- USA Manufactured
EU and UK, Allow 3-5 Working Days For Delivery
Many peptide medicines are approved by the United States Food and Drug Administration. They are used across metabolic health, hormone signalling, digestive health, bone growth, pain, infectious disease and rare conditions.
The range is far wider than the handful of peptide names that usually appear online.
The FDA approves a defined drug product. It does not give a peptide name a universal seal of approval in every possible vial, tablet, pen, formulation or use.
For example, Semaglutide can be an active ingredient in approved medicines, yet a separate product labelled semaglutide is not automatically FDA approved. The same principle applies throughout peptide science.
FDA approval follows a review of evidence for a particular product and intended use. According to the FDA drug approval process, reviewers assess the clinical evidence, the balance of benefits and risks, the proposed label and information about manufacturing and quality.
Approval therefore connects several details. These include the active ingredient, formulation, route, strength, manufacturer, intended population and labelled use. If one of those details changes, a separate application or additional regulatory review may be needed.
This is why it is more accurate to say that the FDA has approved a product containing a peptide than to say that every version of the peptide is approved.
The approved field is already substantial. A 2025 FDA presentation reported that more than 130 FDA approved peptide drug products were designated as reference listed drugs.
A reference listed drug is an approved product that can serve as a point of comparison in generic drug development. The figure describes products rather than 130 completely different peptide sequences, since one active ingredient may appear in more than one product.
A peptide is a chain of amino acids joined by peptide bonds. Amino acids are the smaller building blocks used to form peptides and proteins.
Definitions can vary between scientific fields. For the purpose of its 2023 clinical pharmacology guidance, the FDA uses the term peptide for a polymer containing 40 or fewer amino acids.
The guidance also explains that peptides can be isolated from biological material, produced synthetically or made through recombinant expression.
Many modern peptide medicines are modified versions of natural signalling molecules. A modification may help the peptide remain active for longer, bind more selectively to a target or reach the intended tissue.
Cyclic structures, non natural amino acids, lipid attachments and specialised formulations can all be part of peptide drug design.
The boundary between a peptide and a protein is not identical in every source. This is one reason lists of approved peptide medicines can differ. Insulin, for example, is often discussed alongside peptide hormones in general science, but its 51 amino acids place it beyond the 40 amino acid definition used in this FDA guidance.
This list covers the FDA approved peptide active ingredients explained in this guide. It presents ingredients rather than every approved brand, strength or formulation.
These names refer to active ingredients found in specific FDA approved products.
The approval does not automatically extend to every product sold under the same peptide name.
Metabolic medicine contains some of the most familiar approved peptide products.
Semaglutide, Liraglutide and Tirzepatide are peptide based medicines that interact with pathways involved in glucose regulation and appetite.
Semaglutide and Liraglutide act at the GLP-1 receptor. Tirzepatide acts at both the GIP and the GLP-1 receptor.
The FDA has approved specific products containing these active ingredients for defined uses. Its 2026 guidance update identifies approved products containing Liraglutide, Semaglutide and Tirzepatide.
It also lists the relevant new drug application numbers, which shows how approval is tied to named products rather than the ingredient in isolation.
Other approved metabolic peptides include Exenatide, which also acts at the GLP-1 receptor, and Setmelanotide, which acts at the MC4R in a specific form of genetic obesity.
Glucagon is another established peptide medicine. It is a 29 amino acid hormone involved in glucose regulation. FDA records include approved glucagon products and dasiglucagon, a glucagon analogue designed for greater stability in solution.
These examples show that peptide medicines can support the same broad research area through different receptors, structures and formulations.
They should not be grouped together as though they are interchangeable.
Peptide medicines have a long history in endocrinology, which is the study of hormones and the organs that produce them.
Octreotide, Lanreotide and Pasireotide are somatostatin analogues. An analogue is a molecule designed to resemble another molecule while carrying selected structural changes. These medicines interact with somatostatin receptors and have approved products for specific endocrine and neuroendocrine conditions.
Leuprolide, Goserelin, Triptorelin and Degarelix interact with the gonadotrophin releasing hormone pathway. This pathway helps control signals involved in reproductive hormone production. Different products use agonist or antagonist approaches, so their effects on the receptor are not identical.
Desmopressin is an analogue of vasopressin, while oxytocin is a naturally occurring peptide hormone that also appears as an approved medicine. Tesamorelin is an analogue of growth hormone releasing hormone with a specific FDA approved use.
The range in this group is useful because it shows that approved peptide medicines can copy a natural signal, block a receptor, activate a receptor or alter how long a signal remains available.
Bone and growth research provides another well established group of peptide medicines.
Teriparatide contains the active portion of human parathyroid hormone and is used in approved products for defined osteoporosis populations. Abaloparatide is an analogue related to parathyroid hormone related protein. Calcitonin salmon is a peptide analogue that has also appeared in approved medicinal products.
Vosoritide is a C type natriuretic peptide analogue approved for selected children with achondroplasia. Achondroplasia is a genetic condition that affects bone growth.
This area continued to develop in 2026. The FDA approved Navepegritide, supplied as Yuviwel, as another C type natriuretic peptide analogue for a defined paediatric achondroplasia population. The 2026 FDA label describes it as an approved medicine under the accelerated approval pathway.
Accelerated approval allows the FDA to act on a measure considered reasonably likely to predict clinical benefit while confirmatory work continues.
Some approved oral peptides are designed to act mainly within the digestive tract rather than circulate widely through the body.
Linaclotide and Plecanatide interact with GC-C on the intestinal surface. Their local activity is a useful reminder that an oral peptide does not always need high absorption into the bloodstream to have a defined medicinal role.
Teduglutide is an analogue of GLP-2. It is approved within a specific clinical setting related to short bowel syndrome. Short bowel syndrome occurs when the functioning intestine is unable to absorb enough nutrients and fluids.
The approved peptide field extends well beyond metabolism and hormones.
Ziconotide is a synthetic version of a peptide first identified in cone snail venom. An approved product uses it in the management of severe chronic pain under carefully defined clinical conditions.
Enfuvirtide is a 36 amino acid peptide that interferes with a stage of human immunodeficiency virus entry into cells. Icatibant is a bradykinin receptor antagonist approved for hereditary angioedema, a genetic condition that can cause episodes of swelling. Bremelanotide is a melanocortin receptor agonist with an approved product for a specific sexual health indication.
Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH). The FDA-approved product Egrifta WR is indicated for reducing excess abdominal fat in adults with HIV-associated lipodystrophy. It stimulates the body’s release of growth hormone, which influences fat metabolism. Its approval does not extend to general weight loss or anti-ageing purposes.
Pegcetacoplan is a cyclic peptide based medicine that acts on the complement system, a network of proteins involved in immune activity. FDA approved products containing Pegcetacoplan have different labelled uses and routes, again showing that approval belongs to the complete product.
New approvals continue to widen the field. In 2026, the FDA approved Icotrokinra, supplied as Icotyde, as an oral peptide medicine that blocks the interleukin 23 receptor for a defined plaque psoriasis population. The 2026 FDA label identifies the approved product and its labelled use.
Elamipretide is especially relevant to mitochondrial peptide research. In September 2025, the FDA granted accelerated approval to Forzinity, an Elamipretide injection, for a defined group of people with Barth syndrome. Barth syndrome is a rare genetic condition that affects mitochondrial function.
The FDA approval announcement explains that the product binds within mitochondria and was approved on the basis of a measure considered reasonably likely to predict benefit. A confirmatory study is required as part of the accelerated approval pathway.
This approval also changes how older comparisons should be written. Elamipretide can no longer be described simply as an unapproved research peptide in the United States. The accurate statement is that a specific Elamipretide product has FDA approval for a specific indication and population.
Several peptides studied in laboratory research do not have FDA approved drug products. Examples include BPC-157, CJC-1295, ipamorelin, MOTS-c, Semax, Selank, Epitalon, TB-500 and injectable GHK-Cu.
The 2026 FDA compounding information discusses several of these substances and identifies areas where evidence is limited or product characterisation may be difficult. A separate 2026 advisory committee meeting considered nominations involving BPC-157, KPV, TB-500, MOTS-c, Semax, Epitalon and related substances.
A nomination or advisory committee recommendation does not create an FDA approved medicine. Compounding review and drug approval are separate regulatory processes.
A peptide can still be scientifically valuable without an approved drug product. Its research findings should be explained according to the evidence available rather than presented as established benefits of an approved medicine.
Start with the active ingredient and product name, then check the route and labelled use. The strongest public source is Drugs at FDA, which includes approval records, labels, review documents and regulatory history for most approved medicines.
Read the most recent label rather than relying on a shop page, social post or old article. A label can show the active ingredient, dosage form, route, approved indication, manufacturer and date of revision.
If the exact product does not appear in the database, do not assume that a related ingredient gives it approval. Also check whether the record is active, discontinued or linked to an accelerated approval requirement. Regulatory status can change as new products, indications and formulations are reviewed.
Peptide approval records can be difficult to interpret because one active ingredient may appear in several products, routes and indications.
DN Lab Research offers one to one educational consultations for readers who want help understanding peptide terminology, FDA records, scientific papers and product documentation.
Book your coaching call today.
The FDA approves a defined drug product. The approval includes the active ingredient, formulation, route, manufacturer and labelled use. It does not automatically apply to every product carrying the same peptide name.
No. The FDA has approved specific semaglutide products. A compounded, research or independently marketed version is not automatically covered by those approvals.
No FDA approved drug product containing BPC-157 appears in current FDA approval records. The substance has been discussed through the separate compounding review process, which is not an approval process.
Yes, a specific Elamipretide product called Forzinity received accelerated approval in 2025 for a defined group of people with Barth syndrome. This does not create approval for every Elamipretide product or every proposed use.
Yes. Approved oral peptide medicines include products containing semaglutide, linaclotide and plecanatide. Icotrokinra became another example in 2026. Each product uses a formulation designed around its route and intended target.
Drugs at FDA is the main public database for approval records, labels and review documents. Search using both the active ingredient and product name, then confirm the route and approved indication in the current label.
Written by Elizabeth Tito, BSc Genetics, MPH
Elizabeth is a science and medical writer specialising in peptide science, longevity medicine, mitochondrial health, metabolic optimisation and regenerative health research. With a BSc in Genetics and a Master’s in Public Health, she combines a strong scientific foundation with experience translating complex biomedical research into clear, clinically informed education for the Peptide Therapy and longevity medicine space. Her work is centred on interpreting emerging peptide, metabolic and longevity research with scientific accuracy, clinical awareness and a clear understanding of how these therapies are being discussed and applied in modern health optimisation.
